Rapport Therapeutics, Inc.
News
Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences
Globe Newswire BOSTON and SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...\n more…
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up to $20.40
Ticker Report Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $20.40, but opened at $20.83. Rapport Therapeutics shares...\n more…
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.4%
Ticker Report Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s share price dropped 4.4% on Tuesday . The stock traded as low as $20.93 and last traded at $20.93. Approximately 3,632 shares were traded during...\n more…
Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Globe Newswire BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational...\n more…
RAPP Stock Earnings: Rapport Therapeutics Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nRAPP stock results show that Rapport Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Globe Newswire Completed initial public offering, raising $174.4 million in gross proceeds, including full exercise of the underwriters' option to purchase additional shares and a concurrent private placement, to...\n more…